{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:55:20Z","timestamp":1777532120640,"version":"3.51.4"},"reference-count":11,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pulmonary vein isolation is an effective strategy in patients with atrial fibrillation (<jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>). The peri\u2010procedural use of anticoagulation is routinely employed to reduce thromboembolic risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims\/Methods<\/jats:title><jats:p>The aim of this study was to compare the use of Dabigatran to the other 2 strategies involving the use of Warfarin. Single centre observational study comparing 3 anticoagulation strategies: Group 1 consisted of patients maintained on Warfarin (5.15\u00a0\u00b1\u00a02.52\u00a0mg) with a therapeutic <jats:styled-content style=\"fixed-case\">INR<\/jats:styled-content> of 2\u20133. Group 2 comprised patients initially treated with Warfarin (6.98\u00a0\u00b1\u00a03.17\u00a0mg), which was discontinued 1\u00a0week prior to <jats:styled-content style=\"fixed-case\">LA<\/jats:styled-content> ablation, during which time patients were bridged with a therapeutic dose of Dalteparin. Group 3 included patients anticoagulated with Dabigatran (40 patients received 150\u00a0mg <jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content>, 3 patients received 110\u00a0mg <jats:styled-content style=\"fixed-case\">BID<\/jats:styled-content>), which was discontinued 24\u201330\u00a0h prior to the procedure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 207 patients were included in the study. There were no significant differences in age, sex, <jats:styled-content style=\"fixed-case\">LA<\/jats:styled-content> volume, <jats:styled-content style=\"fixed-case\">CHADS<\/jats:styled-content>2 score or proportion of patients with persistent <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>. There were no significant differences in the number of patients with intra\u2010cardiac thrombus found at <jats:styled-content style=\"fixed-case\">TOE<\/jats:styled-content> (Group 1: 2.3% vs. Group 2: 1.5% vs. Group 3: 0%; <jats:italic>P\u00a0<\/jats:italic>=\u00a00.37). Furthermore, there were no differences in the rate of groin hematoma (2.2% vs. 1.5% vs. 2.3%; <jats:italic>P\u00a0<\/jats:italic>=\u00a00.8) or the development of pericardial effusion (5.4% vs. 8.8% vs. 2.3%; <jats:italic>P\u00a0<\/jats:italic>=\u00a00.54). No thromboembolic events were seen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Peri\u2010procedural use of Dabigatran during <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> ablation procedures is safe, with no significant difference when compared to conventional anticoagulation with either Warfarin bridged with Dalteparin or uninterrupted Warfarin.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12082","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T18:28:01Z","timestamp":1401733681000},"page":"198-201","source":"Crossref","is-referenced-by-count":8,"title":["The Peri\u2010procedural Use of Dabigatran in Patients Undergoing Left Atrial Ablation for Atrial Fibrillation"],"prefix":"10.1111","volume":"32","author":[{"given":"Riyaz","family":"Somani","sequence":"first","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiarash","family":"Mohajer","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Haley","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher S.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoshiar","family":"Abdollah","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Baranchuk","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damian P.","family":"Redfearn","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Michael","sequence":"additional","affiliation":[{"name":"Queen's University Kingston General Hospital Kingston ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,9,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eum120"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2007.00816.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2012.12.011"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12143"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.921320"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/11206400-000000000-00000"},{"key":"e_1_2_7_10_1","first-page":"121","article-title":"Effect of recombinant activated factor VII in critical bleeding: Clinical experience of a single center","volume":"119","author":"Sartori MT","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"e_1_2_7_11_1","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (Abstract 0370)","volume":"93","author":"Ryn J","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.12.014"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12082","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:09:48Z","timestamp":1696360188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,9]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/1755-5922.12082"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12082","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,9]]}}}